---
schema_version: "secwatch.filing_event.v1"
accession: "0001906324-25-000150"
form_type: "8-K"
ticker: "QDEL"
cik: "0001906324"
company_name: "QuidelOrtho Corp"
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T21:03:59.859228+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# QuidelOrtho reports Q2 2025 adjusted EPS of $0.12 vs loss of ($0.07); reaffirms FY guidance

## Summary
- Q2 revenue $614M (-3.6% YoY); Labs revenue +4% as reported, but respiratory revenue fell 20% to $47M on lower COVID-19 sales.
- GAAP net loss $255M ($3.77 loss per share) vs $148M loss prior year; includes $179M restructuring charges, notably $150M Savanna platform discontinuation.
- Adjusted EBITDA $107M (17% margin, +330 bps YoY); achieved $100M annualized cost savings from 2024 initiatives.
- Reiterates FY2025 guidance: revenue $2.60-$2.81B, adj. EBITDA $575-$615M, adj. diluted EPS $2.07-$2.57.
- Announced intent to acquire LEX Diagnostics; initiated major manufacturing site consolidation.

## SEC filing metadata
- accession: 0001906324-25-000150
- form_type: 8-K
- ticker: QDEL
- cik: 0001906324
- company_name: QuidelOrtho Corp
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1906324/000190632425000150/0001906324-25-000150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1906324/000190632425000150/qdel-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001906324-25-000150
- JSON: https://secwatch.observer/filing/0001906324-25-000150.json
- Plain text: https://secwatch.observer/filing/0001906324-25-000150.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.